Prodrugs incorporated into nanotechnology-based drug delivery systems for possible improvement in bioavailability of ocular drugs delivery  

作　　者：Tiantian Ye Kun Yuan Wenji Zhang Shuangshuang Song Fen Chen Xinggang Yang Shujun Wang Jianwei Bi Weisan Pan 

机构地区：[1]School of Pharmacy,Shenyang Pharmaceutical University,Shenyang 110016,China [2]Shangdong Wego Pharmaceutical Co.Ltd,Weihai 264209,China

出　　处：《Asian Journal of Pharmaceutical Sciences》2013年第4期207-217,共11页亚洲药物制剂科学（英文）

基　　金：special construction projects fund which belongs to“Taishan Scholar-Pharmacy Specially Recruited Experts”.

摘　　要：Numerous systems have been designed during the past three decades to improve bioavailability of ophthalmic drug delivery,including:ocular prodrugs and nanotechnology-based drug delivery system.The former can improve the efficacy of ocular drug via enhancing corneal penetration of ocular drugs,prolonging their duration of action and/or reducing the systemic side-effects,unfortunately,some characteristics of the pro-drugs,such as poorly aqueous stability,poorly aqueous solubility and severe eye irritation probably,limit their clinical practice and cannot be ignored.As we all know,nanotech-nology for ocular drug delivery can carry poorly soluble drugs,protect the encapsulated molecules from hydrolysis,control the rate of drug delivery and prolong the precorneal retention of drugs.All of these merits may solve the problems in the utilization of ocular prodrugs and increase the bioavailability of ocular drug delivery.By reviewing recent ad-vances of prodrugs and nanostructures in ocular drug delivery,this paper focus specifically on the promising prospects of nanocarriers overcoming the drawbacks of prodrugs for ophthalmic drug delivery by precorneal routes.

关 键 词：Ocular/ophthalmic drug delivery PRODRUGS NANOCARRIERS Penetration Precorneal retention BIOAVAILABILITY 

分 类 号：R96[医药卫生—药理学]